Affordable Access

deepdyve-link
Publisher Website

Antiplatelet drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

Authors
  • Patrono, Carlo1
  • Baigent, Colin2
  • Hirsh, Jack3
  • Roth, Gerald4
  • 1 From the Catholic University School of Medicine, Rome, Italy. Electronic address: [email protected] , (Italy)
  • 2 Clinical Trial Service Unit, University of Oxford, Oxford, UK.
  • 3 Hamilton Civic Hospitals, Henderson Research Centre, Hamilton, ON, Canada. , (Canada)
  • 4 Seattle VA Medical Center, Seattle, WA.
Type
Published Article
Journal
Chest
Publisher
Elsevier BV
Publication Date
Jun 01, 2008
Volume
133
Issue
6 Suppl
Identifiers
DOI: 10.1378/chest.08-0672
PMID: 18574266
Source
Medline
Language
English
License
Unknown

Abstract

This article about currently available antiplatelet drugs is part of the Antithrombotic and Thrombolytic Therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). It describes the mechanism of action, pharmacokinetics, and pharmacodynamics of aspirin, reversible cyclooxygenase inhibitors, thienopyridines, and integrin alphaIIbbeta3 receptor antagonists. The relationships among dose, efficacy, and safety are thoroughly discussed, with a mechanistic overview of randomized clinical trials. The article does not provide specific management recommendations; however, it does highlight important practical aspects related to antiplatelet therapy, including the optimal dose of aspirin, the variable balance of benefits and hazards in different clinical settings, and the issue of interindividual variability in response to antiplatelet drugs.

Report this publication

Statistics

Seen <100 times